Scholars Central

Conference abstractPublished 9 Mar 2018

Development of a chlamydial vaccine for koalas: Protection against infection as well as disease

Authors: Peter Timms

University of the Sunshine Coast, Australia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Wild koala populations continue to experience serious declines as a result of several threatening factors including: loss of habitat; motor vehicle trauma; dog attacks and; chlamydial disease. Chlamydial infections are associated with diseases ranging from ocular disease leading to blindness, as well as urinary and genital tract disease, leading to female infertility. Modeling shows that targeting chlamydial disease would have a major impact on stabilizing population decline. Our previous studies have demonstrated that koalas can be safely immunized with a vaccine containing a mixture of chlamydial major outer membrane protein (MOMP) antigens combined with a single or three-dose subcutaneous regime. In our most recent, large scale, field trial of the vaccine, we vaccinated 30 koalas that were outwardly clinically healthy but either chlamydia PCR negative or chlamydia PCR positive, and followed them for 1-2 years to assess the protective effect of the vaccine (compared to a control group of unvaccinated koalas). We observed strong, specific and long-lasting immune responses in the vaccinated koalas; high titer antibody responses (as measured by ELISA and also in vitro neutralization) as well as chlamydia-specific cytokine responses (interferon-gamma and IL-17 in particular). For animals which were chlamydia PCR positive at the time of vaccination, we observed a significant reduction in their infection PCR load (at both the ocular and urogenital tract sites). We also observed protection from progression to clinical disease in the vaccinated animals. We have also conducted a small trial to vaccinate animals which already have clinical signs of ocular disease. Instead of the normal practice of administering antibiotics (chloramphenicol, daily for 28 days, which severely disrupts the animalâÂ?Â?s gut microbiome) we vaccinated four animals with a single dose, 3-MOMP vaccine. For all vaccinated animals, their chlamydia PCR load decreased, often to zero, and in two animals at least, we observed a decrease in their clinical disease score. These results are promising for the future development of an effective chlamydial vaccine for use in captive as well as wild koalas. Recent publications 1. Timms P (2017) Novel strategies for developing vaccines bring encouraging progress. Pathogens and Disease 29:75. 2. Desclozeaux M, Robbins A, Jelocnik M, Khan S, Hanger J, Gerdts V, Potter A, Polkinghorne A and Timms P (2017) Immunization of a wild koala population with a recombinant Chlamydia pecorum Major Outer Membrane Protein (MOMP) or Polymorphic Membrane Protein (PMP) based vaccine: New insights on immune response, protection and clearance. PLoS One 12(6):e0178786. 3. Desclozeaux M, Jelocnik M, Timms P, Whitting K, Saifzadeh S, Bommana S, Potter A, Gerdts V and Polkinghorne A (2017) Safety and immunogenicity of a prototype anti-chlamydia pecorum recombinant protein vaccine in lambs and pregnant ewes. Vaccine 35: 3461âÂ?Â?3465. 4. Marsh J, Ong V, Lott W, Tyndall J, Timms P and Huston W (2017) Chlamydia trachomatis HtrA: the lynch pin of the chlamydial surface and a promising therapeutic agent. Future Microbiology 12:817âÂ?Â?829. 5. Lau A, Kong F, Fairley C, Donovan B, Chen M, Bradshaw C, Boyd M, Amin J, Timms P, Tabrizi S, Regan D, McNulty A and Hocking J (2017) Treatment efficacy of azithromycin 1g single dose versus doxycycline 100mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double blind randomised controlled trial protocol. BMC Infectious Diseases 17:35.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Therapy
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Peter Timms”